Authors


John Gilbert

Latest:

Making the Most of Maturing Oncology Brands

A checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there’s hidden vitality still left in their aging brands.


Bob Josefsberg

Latest:

Making the Most of Maturing Oncology Brands

A checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there’s hidden vitality still left in their aging brands.


Sabina Heinz and Elizabeth Baynton

Latest:

NASH: Still Waiting

Sabina Heinz and Elizabeth Baynton look at how the continued absence of approved products affecting the management of NASH patients.


William Kirsh

Latest:

Drug Formulary Decisions: Fixing a Broken System

Why the time is right for P&T committees to incorporate real-world data and ‘real-world science’ into their product assessments.


Barbara Arone

Latest:

The Argument for External Comparator Adoption

Its use, new data shows, could boost the economic benefit profile of more “common” drugs-and better inform HTA and payer decision-making.


Lauren Seufert

Latest:

'Vision’ Quest: Leading Through Change

Exploring the critical go-to strategies for biopharma C-suite executives in navigating organizational disruption and the impact of global change and volatility on their employees and business.


Siva Thiagarajan

Latest:

Transforming PV in Smaller Companies with Standardization and Automation

Small- and medium-sized pharmas should revisit their pharmacovigilance strategies and adopt smarter end-to-end solutions to keep pace with increased volumes and rapidly changing regulatory requirements, writes Siva Thiagarajan.


Parth Khanna

Latest:

Clinical Evidence Key to Commercializing Life Science Products

Companies need to find compelling ways to present facts, rather than slick but insubstantial promotions.


Aarthi Iyer

Latest:

The Feasibility of Patient Insights Before Launch

Obtaining patient perspectives during open-label extension trials.


Ross Weaver

Latest:

The Feasibility of Patient Insights Before Launch

Obtaining patient perspectives during open-label extension trials.


George Lee

Latest:

Patient-Centric Trials in China: An Opportunity to Innovate

The opportunities and challenges surrounding patient centricity and patient-centric trials in China.


Alberto Grignolo

Latest:

Patient-Centric Trials in China: An Opportunity to Innovate

The opportunities and challenges surrounding patient centricity and patient-centric trials in China.


Rosamund Round

Latest:

Patient-Centric Trials in China: An Opportunity to Innovate

The opportunities and challenges surrounding patient centricity and patient-centric trials in China.


Sy Pretorius

Latest:

Patient-Centric Trials in China: An Opportunity to Innovate

The opportunities and challenges surrounding patient centricity and patient-centric trials in China.


Victor Cheng

Latest:

Patient-Centric Trials in China: An Opportunity to Innovate

The opportunities and challenges surrounding patient centricity and patient-centric trials in China.


Leo Grimaldi, MD

Latest:

The Shrinking Disconnect in Digital Therapeutics

More signs of alignment between startups, pharma, and payers.


Dean Hakanson, Jon Gonzales, and Tara Alire

Latest:

Using FDA’s ‘PIE’ Recipe to Enhance Patient Access

How R&D organizations can leverage FDA’s final guidance on pre-approval information exchange (PIE) to engage with payers prior to approval and launch.


Melonie Warfel

Latest:

The Revenue Crises: Driving Pharma Companies to Change Revenue Management Tactics

Melonie Warfel discusses the challenges organizations are facing when it comes to revenue management and looks at the key areas to optimize.


Steve Figman and Sean Robertson

Latest:

Shared Understanding Creates Culture

While culture may "eat" strategy, shared understanding creates both culture and strategy, write Steve Figman and Sean Robertson.


Brad Pedrow

Latest:

Compliance as Usual Doesn’t Cut it Anymore

How pharma companies can bolster their quality management programs to meet FDA’s evolving compliance requirements.



Monika Vytiskova

Latest:

Translation Automation: A Viable Solution?

Global content management needs are mounting among life sciences organizations, as they expand their market coverage and grapple with multiplying regulatory workloads. Monica Vytiskova asks if can intelligent automation offer a solution.


Gina Parry

Latest:

Keeping Up with Telehealth: Pharma’s Evolution

If telehealth is here to stay, how is the industry adjusting?




Francesco Lucarelli

Latest:

How to Harness, Leverage Key Online Influencers

The importance of KOIs in tapping into today’s market mindset.


Colin Foster

Latest:

How to Harness, Leverage Key Online Influencers

The importance of KOIs in tapping into today’s market mindset.


Clark Herman

Latest:

CEOs Sound Out on Health Reform: Stop Swinging from the Fence

At last week’s 4th annual Prix Galien Forum hosted by the Alexandria Center in New York, industry leaders gathered to discuss trends and developments that shape the intersection between science and policy.


Sven Klingemann

Latest:

Restoring Pharma's Reputation

A 2019 study reveals further marginal decline in the pharma industry's reputation. Sven Klingemann suggests some "recovery solutions".


Christopher R. Smith

Latest:

Policy Sync-Up: The Drug Importation Conundrum

Coexisting with the DSCSA may hinder new legislative efforts.